Pharmacists, your moment to lead in chronic care.
The new dyslipidemia guideline: Not just another update
Let’s be honest: most clinical guidelines feel like they’re written for someone else. But the 2026 ACC/AHA Dyslipidemia Guideline is different. This isn’t just a clinical roadmap, it’s a direct call to pharmacists to step up and lead chronic disease management in a landscape that finally recognizes your role.
With the American Pharmacists Association (APhA) now a formal endorser, pharmacy is no longer on the sidelines. The only question left: Will you act on this opportunity?
Three ways the guideline puts pharmacists center stage
1. Lp(a) testing advocacy: Bringing hidden risk to light
For the first time, the guideline recommends universal screening for Lp(a) in adults, with special guidance for children under 18. Lp(a) is a sneaky, independent risk factor for heart disease, and it’s rarely checked in primary care.
Here’s the opportunity: Every time you conduct a medication therapy management (MTM) review, ask, “Has your Lp(a) ever been checked?” If not, flag it in the patient’s medication action plan for their prescriber. One simple question could make a life-changing difference.
2. Navigating statin intolerance: Beyond the basics
Statins are still the backbone, but now the guideline formally includes new alternatives, bempedoic acid, PCSK9 inhibitors, ezetimibe, in its stepwise approach.
As a pharmacist, you see when patients struggle with statin side effects, and you’re in the perfect position to know when it’s time to recommend stepping up therapy. Understanding when to move from ezetimibe to a PCSK9 inhibitor, or eventually to new agents like enlicitide, makes you the bridge between policy and patient care.
3. Earlier and lower for longer: A cultural reset
The biggest shift? We’re moving from treating after a heart attack to preventing one, sometimes starting intervention as early as age 30 for high-risk adults. It’s a whole new mindset, one that values proactive counseling and early intervention.
If you start conversations with younger adults about cholesterol, you’re ahead of the curve, and helping reshape what “prevention” really means.
Why pharmacists are uniquely positioned
Let’s break it down:
- You see patients on statins every month, while their doctors may see them once a year.
- You spot non adherence in real time, those refill gaps tell a story no one else sees.
- You can cross check lab values and LDL targets instantly and know when someone isn’t at goal.
- You’re the first person patients ask about side effects, new drugs they saw online, or dose changes.
In short: You’re not just part of the care team, you’re its most consistent member.
What skills do you need right now?
- Fluency in the 2026 PREVENT risk calculator (it’s replacing those old Pooled Cohort Equations, get familiar, fast).
- Understanding when Lp(a) and ApoB matter enough to change a care plan.
- Mastery of the stepped care algorithm: Start high-intensity statin → add ezetimibe → escalate to PCSK9 inhibitor or bempedoic acid → consider enlicitide.
- Ability to write concise, evidence-based recommendations for prescribers, your interventions should be actionable, not just informative.
Your action step for this week
Open your pharmacy system. Pull up a list of patients who are refilling both high-intensity statins and ezetimibe. These are the folks at highest risk, and most likely not at goal. Each is an opportunity for a pharmacist-driven intervention.
Ask yourself: What’s one question, one clinical note, or one phone call I can make that moves their care forward?
The bottom line
This isn’t about waiting for someone else to invite you to the table. The 2026 guideline has already done that. The future of chronic care is here, and you’re at the center of it.
Are you ready to take the lead?